Navigation Links
New Brandeis research sheds light on memory by erasing it

For years, scientists have studied the molecular basis of memory storage, trying to find the molecules that store memory, just as DNA stores genetic memory. In an important study published this week in the Journal of Neuroscience, Brandeis University researchers report for the first time that memory storage can be induced and then biochemically erased in slices of rat hippocampus by manipulating a so-called "memory molecule," a protein kinase known as CaMKII.

"The core problem in memory research has been understanding what the storage molecule actually is. Identifying this molecule is essential to understanding memory itself as well as any disease of memory, " explained lead author John Lisman. "With this study, we have confirmed CaMKII as a memory molecule."

The research involved electrically stimulating neuronal synapses to strengthen them, a process known as long-term potentiation (LTP). This process has served as a model system for studying memory. CaMKII has been a leading candidate as a memory molecule because it is persistently activated after LTP induction and can enhance synaptic transmission, properties that are necessary for a memory molecule.

Like a computer whose electronics change with the addition of new information, molecular activity in the hippocampus, where memory is stored in the brain, changes as memory is being stored. In this study, Lisman and his colleagues showed that they could saturate the memory stores. However, when CaMKII was chemically attacked and previous memory erased, it then became possible to insert new memories in the synapses.

Alzheimer's and other diseases in which memory loss plays a major role will benefit from this new understanding. Of particular importance may be conditions like epilepsy, which involves synapses that have become overly strengthened. The new research shows how synapses can be weakened by attacking memory molecules.

Lisman's lab plans further research to bet ter understand what happens to the CaMKII after it is attacked. By using fluorescent forms of CaMKII, it will be possible to determine whether the kinase leaves the synapse after inhibitor is applied. This provides a way to directly visualize the forgetting process and complements previous work done in Lisman's laboratory showing that when LTP is induced (as during learning), CaMKII moves into the synapse.


'"/>

Source:Brandeis University


Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology: